Lymphangioleiomyomatosis: A Disease Involving the Lymphatic System
- 1 March 2010
- journal article
- review article
- Published by Mary Ann Liebert Inc in Lymphatic Research and Biology
- Vol. 8 (1), 21-31
- https://doi.org/10.1089/lrb.2009.0018
Abstract
Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease in which abnormal smooth muscle-like cells (LAM cells) proliferate in the lungs and along the axial lymphatic systems, including the lymph nodes and thoracic ducts. LAM cells are transformed due to loss-of-function type mutations of either the TSC1 or TSC2 tumor suppressor genes. The pathological features include the proliferation of benign-looking LAM cells and the existence of abundant lymphatic vessels that are associated with clinical conditions such as chyle leakage. LAM cells produce potent lymphangiogenic growth factors (VEGF-C and VEGF-D) and the lymphatic vessel density within LAM lesions correlates with the histologic severity of LAM. The serum VEGF-D level increases in LAM, especially in patients with lymphatic involvement. LAM cell clusters (LCCs), which are postulated pathologically to be generated by lymphangiogenesis-mediated fragmentation and subsequent shedding into the lymphatic circulation, are observed in both chylous effusion and LAM-associated lymphatics within LAM tissue specimens. The identification of LCCs in chylous effusion together with the characteristic clinical manifestations can therefore be an alternative for a lung biopsy if LAM patients are complicated with chylous effusion. LAM appears to be a disease involving a dysfunction of the lymphatic system and a fascinating model of tumor dissemination that is exclusively lymphangitic. LAM-associated lymphangiogenesis that mediates the shedding of LCCs seems to play a central role in the dissemination of LAM cells and progression in LAM and it may also be a potential therapeutic target as well as the dysregulated mTOR signaling pathway.Keywords
This publication has 96 references indexed in Scilit:
- Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic InvolvementSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- Sirolimus Amelioration of Clinical Symptoms of Recurrent Lymphangioleiomyomatosis After Living-donor Lobar Lung TransplantationThe Journal of Heart and Lung Transplantation, 2008
- Effect of a Gonadotrophin-Releasing Hormone Analogue on Lung Function in LymphangioleiomyomatosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisThe New England Journal of Medicine, 2008
- Chylothoraces After Lung Transplantation for Lymphangioleiomyomatosis: Review of the Literature and Utilization of a Pleurovenous ShuntThe Journal of Heart and Lung Transplantation, 2007
- Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and MetastasisThe American Journal of Pathology, 2007
- Inhibition of the mammalian target of rapamycin impedes lymphangiogenesisKidney International, 2007
- An Invasion-Independent Pathway of Blood-Borne Metastasis: A New Murine Mammary Tumor ModelThe American Journal of Pathology, 2002
- Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosisJournal of Human Genetics, 2002
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences of the United States of America, 1971